Gilead Sciences is trading 4.23% up at ARS 56675.00 after continued investor response to its August 4 second-quarter report, which showed product sales rising 8% and strong HIV-drug performance.
- Reuters reported the quarter included a loss linked to acquisition costs.
- Other coverage highlighted sales beating expectations and improved full-year guidance.
- The gain is notable as broader U.S. markets are lower; no separate August 18 announcement was identified.